Provided by Tiger Fintech (Singapore) Pte. Ltd.

Intra-Cellular Therapies

131.87
0.0000
Volume:- -
Turnover:2.12B
Market Cap:14.02B
PE:-182.12
High:131.87
Open:131.87
Low:131.87
Close:131.87
Loading ...

Should Schwab U.S. Small-Cap ETF (SCHA) Be on Your Investing Radar?

Zacks
·
08 Apr

Intra-Cellular Therapies Price Target Maintained With a $132.00/Share by Cantor Fitzgerald

Dow Jones
·
02 Apr

Intra-Cellular Therapies (ITCI) Receives a Rating Update from a Top Analyst

TIPRANKS
·
02 Apr

Johnson & Johnson completes Intra-Cellular Therapies acquisition, sees dilution

TIPRANKS
·
02 Apr

Press Release: Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience Leadership

Dow Jones
·
02 Apr

Beam Therapeutics (BEAM) Down 21.4% Since Last Earnings Report: Can It Rebound?

Zacks
·
27 Mar

Jefferies profit misses estimates as bond trading, equity underwriting weaken

Reuters
·
27 Mar

Here's How to Play JNJ Stock as it Announces $55B US Investment Plan

Zacks
·
24 Mar

BRIEF-Intra-Cellular Therapies stockholder filed lawsuit against co, board in NY Supreme Court

Reuters
·
19 Mar

Intra-Cellular Therapies- on Feb 26, Stockholder Filed Lawsuit Against Co and Board in New York Supreme Court - SEC Filing

THOMSON REUTERS
·
19 Mar

Intra-Cellular Therapies Inc - Believes Lawsuit Claims Are Without Merit

THOMSON REUTERS
·
19 Mar

Is Intra-Cellular Therapies, Inc. (ITCI) a Best Biotech Stock According to Billionaires?

Insider Monkey
·
18 Mar

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

Dow Jones
·
14 Mar

JNJ Halts Development of Depression Drug Over Efficacy Concerns

Zacks
·
08 Mar

Johnson & Johnson Stops Late-Stage Depression Study Over 'Insufficient Efficacy'

Benzinga
·
07 Mar

Intra-Cellular Therapies, Inc. (ITCI): Among the Best Psychedelic Stocks to Buy in 2025

Insider Monkey
·
02 Mar

Intra-Cellular Therapies Reports Strong 2024 Growth

TIPRANKS
·
25 Feb

ITCI Q4 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales

Zacks
·
25 Feb

Intra-Cellular Therapies Cut to Neutral From Outperform by Mizuho

Dow Jones
·
24 Feb

Mizuho Downgrades Intra-Cellular Therapies to Neutral From Outperform, Lowers Price Target to $132 From $140

MT Newswires Live
·
24 Feb